Premium
Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis
Author(s) -
Gillmore J. D.,
Stangou A. J.,
Lachmann H. J.,
Goodman H. J.,
Wechalekar A. D.,
Acheson J.,
Tennent G. A.,
Bybee A.,
Gilbertson J.,
Rowczenio D.,
O'Grady J.,
Heaton N. D.,
Pepys M. B.,
Hawkins P. N.
Publication year - 2006
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2006.01507.x
Subject(s) - medicine , amyloidosis , transplantation , al amyloidosis , organ transplantation , surgery , pathology , immunology , immunoglobulin light chain , antibody
Patients with hereditary apolipoprotein AI (apoAI) amyloidosis often have extensive visceral amyloid deposits, and many develop end‐stage renal failure as young adults. Solid organ transplantation to replace failing organ function in systemic amyloidosis is controversial due to the multisystem and progressive nature of the disease and the risk of recurrence of amyloid in the graft. We report the outcome of solid organ transplantation, including dual transplants in 4 cases, among 10 patients with apoAI amyloidosis who were followed for a median (range) of 16 (4–28) and 9 (0.2–27) years from diagnosis of amyloidosis and transplantation, respectively. Eight of 10 patients were alive, seven with a functioning graft at censor. Two patients died, one of disseminated cytomegalovirus infection 2 months after renal transplantation and the other of multisystem failure following severe trauma more than 13 years after renal transplantation. The renal transplant of one patient failed due to recurrence of amyloid after 25 years. Amyloid disease progression was very slow and the natural history of the condition was favorably altered in both cases in which the liver was transplanted. Failing organs in hereditary apoAI amyloidosis should be replaced since graft survival is excellent and confers substantial survival benefit.